Annexon, Inc. (NASDAQ:ANNX) Insider Jamie Dananberg Sells 5,521 Shares of Stock

Annexon, Inc. (NASDAQ:ANNX) insider Jamie Dananberg sold 5,521 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $2.96, for a total value of $16,342.16. Following the sale, the insider now owns 33,479 shares of the company’s stock, valued at $99,097.84. This represents a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Annexon Price Performance

Shares of ANNX stock opened at $2.83 on Friday. The firm has a fifty day moving average of $4.29 and a two-hundred day moving average of $5.57. The firm has a market cap of $301.66 million, a P/E ratio of -2.70 and a beta of 1.07. Annexon, Inc. has a 1-year low of $2.63 and a 1-year high of $8.40.

Wall Street Analyst Weigh In

ANNX has been the topic of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Annexon in a research note on Tuesday, December 17th. Needham & Company LLC restated a “buy” rating and set a $16.00 target price on shares of Annexon in a research note on Friday, November 15th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a research note on Friday, November 15th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $15.80.

Hedge Funds Weigh In On Annexon

A number of hedge funds have recently bought and sold shares of ANNX. BNP Paribas Financial Markets bought a new stake in Annexon during the fourth quarter valued at $59,000. CANADA LIFE ASSURANCE Co acquired a new position in shares of Annexon during the fourth quarter worth approximately $77,000. E Fund Management Co. Ltd. boosted its position in Annexon by 36.0% during the 4th quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company’s stock worth $79,000 after acquiring an additional 4,086 shares during the period. Forefront Analytics LLC lifted its holdings in Annexon by 56.8% in the fourth quarter. Forefront Analytics LLC now owns 16,433 shares of the company’s stock worth $84,000 after purchasing an additional 5,950 shares during the period. Finally, KLP Kapitalforvaltning AS bought a new position in shares of Annexon in the fourth quarter valued at approximately $98,000.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.